HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s OPaSS promotion

This article was originally published in The Tan Sheet

Executive Summary

Deputy Director of the Office of Pharmacoepidemiology & Statistical Science (OPaSS) will be Jonca Bull, MD, FDA states May 2; the announcement is effective immediately. OPaSS Director Paul Seligman, MD, said Bull "will be responsible for the development and implementation of many of the drug safety and statistical strategic initiatives in OPaSS, in addition to assisting me with the management of the office." She most recently served as director of Office of Drug Evaluation V, which is being eliminated as part of CDER's reorganization (1"The Tan Sheet" Oct. 25, 2004, p. 3)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts